Effects of sleep apnoea therapy on blood pressure and metabolism: a CPAP sex gap?. Issue 2 (10th August 2017)

• Record Type: Journal Article
• Authors: Gagnadoux, Frédéric; Priou, Pascaline; Meslier, Nicole; Trzepizur, Wojciech
• Is Part Of: European respiratory journal. Volume 50:Issue 2(2017)
• Publication Date: 2017-08-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00987-2017
• Languages: English
• ISSNs: 0903-1936

Abstract

Obstructive sleep apnoea (OSA) is a highly prevalent disease characterised by recurrent episodes of complete or partial upper airway obstruction during sleep, leading to intermittent hypoxia and sleep fragmentation. Most recent estimates of OSA prevalence suggest that 13% of men and 6% of women have clinically significant OSA [1, 2]. There is evidence from population-based and clinic-based cohort studies that moderate-to-severe OSA is independently associated with an increased incidence of cardiovascular events [3, 4]. Besides OSA-related variables, comorbid conditions including hypertension and metabolic dysfunction play an important role in the development of cardiovascular diseases in OSA patients [4]. In the clinical setting, it has been estimated that at least half of patients with OSA fulfil the criteria for the metabolic syndrome [5]. Furthermore, the prevalence of metabolic syndrome increases with OSA severity [5, 6]. An independent dose–response relationship has been demonstrated between OSA severity and the features of metabolic syndrome, including visceral adiposity [7], hypertension [8], metabolic dyslipidaemia [6] and impaired glucose metabolism [9, 10]. Considering cardiovascular prevention as a therapeutic objective in OSA patients, it is crucial to determine whether OSA therapy can lead to clinically relevant improvements in blood pressure, and glucose and lipid metabolism. CPAP therapy reduces blood pressure but has no impact on metabolic profile in women with sleep apnoea http://ow.ly/AAKj30cQb6X